Vestibular Disease

Vestibular disease is a clinical syndrome resulting from dysfunction of the vestibular system, which is responsible for maintaining balance, coordination, and spatial orientation. The vestibular system comprises peripheral components (vestibular receptors in the inner ear, vestibular nerve) and central components (vestibular nuclei in the brainstem, cerebellum, and their connections). Vestibular disease can be classified as peripheral or central based on the anatomical location of the lesion. Peripheral vestibular disease is more common and generally carries a better prognosis, while central vestibular disease indicates brainstem or cerebellar involvement and may be life-threatening. Clinical signs include head tilt, nystagmus, ataxia, circling, falling, and sometimes nausea and vomiting. The syndrome can be acute or chronic, and may be caused by a wide range of etiologies including infections, toxins, trauma, neoplasia, and idiopathic causes.

The etiologies of vestibular disease are diverse and depend on whether the lesion is peripheral or central. Peripheral vestibular disease can result from otitis media/interna (bacterial, fungal, or parasitic), trauma to the temporal bone, ototoxic drugs (e.g., aminoglycosides, furosemide), idiopathic vestibular syndrome (especially in geriatric dogs and cats), polyps or neoplasia of the middle ear (e.g., squamous cell carcinoma, ceruminous gland adenocarcinoma), and congenital malformations. Central vestibular disease may be caused by inflammatory/infectious diseases (e.g., canine distemper virus, feline infectious peritonitis, toxoplasmosis, neosporosis, cryptococcosis, blastomycosis, histoplasmosis), ischemic or hemorrhagic stroke (cerebrovascular accident), neoplasia (e.g., meningioma, glioma, lymphoma, metastatic tumors), trauma, thiamine deficiency, and toxins (e.g., lead, metronidazole, ivermectin). In many cases, the exact cause remains unknown (idiopathic).

Vestibular disease occurs in both dogs and cats. Idiopathic vestibular syndrome is common in geriatric dogs (often termed 'old dog vestibular syndrome') and can also affect cats of any age. Breed predispositions for peripheral vestibular disease include those with a high incidence of otitis externa/media, such as Cocker Spaniels, Labrador Retrievers, and Golden Retrievers. Congenital vestibular disease has been reported in certain breeds, including German Shepherds, Doberman Pinschers, and English Cocker Spaniels. Central vestibular disease may reflect breed predispositions to brain tumors (e.g., Boxers, Boston Terriers, Golden Retrievers for meningiomas). No sex predilection is consistently reported. Geographic variations exist for infectious causes, such as fungal infections in endemic areas (e.g., blastomycosis in the Mississippi River Valley).

The vestibular system detects head position and movement via hair cells in the semicircular canals and otolith organs (utricle and saccule). These signals are transmitted via the vestibular nerve to the vestibular nuclei in the brainstem and then to the cerebellum, spinal cord, and oculomotor nuclei. Unilateral dysfunction creates an asymmetry in neural firing, leading to the clinical signs of head tilt, nystagmus, and ataxia. Peripheral lesions affect the vestibular receptors or nerve, while central lesions involve the brainstem or cerebellum. In otitis media/interna, bacterial infection causes inflammation and destruction of the inner ear structures. In ischemic stroke, interruption of blood flow leads to neuronal death and loss of vestibular function. Inflammatory diseases cause demyelination and neuronal damage. Idiopathic vestibular syndrome is thought to involve a viral or immune-mediated inflammation of the vestibular nerve, but the exact mechanism remains unclear. The body may compensate over time through central adaptation, which explains the gradual improvement seen in many cases.

Predisposing factors for vestibular disease include advanced age (idiopathic vestibular syndrome), chronic ear infections (otitis externa/media), trauma to the head, exposure to ototoxic drugs, metabolic diseases (e.g., hypothyroidism), and immunosuppression (increasing susceptibility to infections). Breed-specific genetic factors may predispose to congenital vestibular disease. Environmental factors such as access to toxins (e.g., lead, metronidazole overdose) or infectious agents (e.g., fungal spores) also play a role. Concurrent systemic diseases, such as hypertension or hyperadrenocorticism, may increase the risk of cerebrovascular accidents leading to central vestibular signs.

Clinical signs of vestibular disease include head tilt (usually toward the side of the lesion), nystagmus (horizontal, rotary, or vertical; peripheral nystagmus is typically horizontal or rotary and does not change direction with head position, while central nystagmus may be vertical or positional), ataxia (often with a wide-based stance and tendency to fall or circle toward the lesion side), and sometimes strabismus (ventrolateral strabismus on the affected side). In acute cases, affected animals may show severe disorientation, nausea, vomiting, and anorexia. Peripheral vestibular disease often presents with normal mentation and proprioception, whereas central vestibular disease may be accompanied by altered mentation, proprioceptive deficits, cranial nerve deficits (e.g., facial nerve paralysis, Horner's syndrome), and other brainstem signs. In chronic cases, clinical signs may be less severe due to central compensation.

Differential diagnoses for vestibular disease include: 1) Otitis media/interna (peripheral) - history of ear infection, otoscopic findings, imaging evidence of middle ear disease. 2) Idiopathic vestibular syndrome (peripheral) - acute onset in geriatric animals, no other neurological deficits, spontaneous improvement. 3) Brainstem neoplasia (central) - progressive course, MRI findings, cerebrospinal fluid analysis. 4) Cerebrovascular accident (central) - peracute onset, MRI evidence of infarction or hemorrhage. 5) Inflammatory/infectious meningoencephalitis (central) - CSF analysis, infectious disease titers/PCR. 6) Toxicity (e.g., metronidazole, lead) - history of exposure, response to withdrawal. 7) Trauma - history, imaging evidence of skull fractures. 8) Thiamine deficiency - dietary history, response to thiamine supplementation. 9) Congenital vestibular disease - young age, breed predisposition, no progression. 10) Vestibular nerve sheath tumor (peripheral) - MRI findings, progressive course.

The diagnostic approach begins with a thorough history and physical examination, including a complete neurological examination to differentiate peripheral from central vestibular disease. Key steps: 1) Assess mentation, postural reactions, and cranial nerves. If proprioceptive deficits or altered mentation are present, central disease is likely. 2) Perform otoscopic examination to evaluate for otitis externa/media. 3) If peripheral disease is suspected, consider imaging of the tympanic bullae (radiography, CT, or MRI) to rule out middle ear disease. 4) If central disease is suspected, advanced imaging (MRI preferred) of the brain is indicated. 5) Cerebrospinal fluid analysis (CSF) should be performed if inflammatory/infectious disease is suspected, but only after imaging to rule out increased intracranial pressure. 6) Baseline blood work (CBC, biochemistry, urinalysis) and blood pressure measurement to identify metabolic or hypertensive causes. 7) Specific tests: thyroid function (hypothyroidism), infectious disease titers/PCR (e.g., Toxoplasma, Neospora, Cryptococcus, FeLV/FIV), and toxicology screens if exposure is suspected. 8) In cases of suspected idiopathic vestibular syndrome, diagnosis is based on exclusion of other causes.

Laboratory findings are often unremarkable in peripheral vestibular disease. In central vestibular disease, CBC may show leukocytosis or left shift if infection is present. Serum biochemistry may reveal elevated liver enzymes or hyperglycemia due to stress, or specific abnormalities such as hypercalcemia (neoplasia) or hypoglycemia (insulinoma). Urinalysis may show evidence of urinary tract infection if systemic infection is present. Blood gas analysis may indicate metabolic acidosis if vomiting is severe. Specific biomarkers: In inflammatory brain disease, CSF analysis typically shows increased protein and nucleated cell count (lymphocytic or neutrophilic pleocytosis). Infectious disease titers (e.g., Toxoplasma IgG/IgM, Neospora, Cryptococcus antigen) may be positive. In cases of thiamine deficiency, blood thiamine levels may be low. Thyroid hormone levels (T4, TSH) may be low in hypothyroid dogs with vestibular signs.

Radiography of the skull (including open-mouth view) may reveal fluid or bone lysis in the tympanic bullae in otitis media/interna, but is less sensitive than CT or MRI. Ultrasonography is not typically used for vestibular disease. Computed tomography (CT) is excellent for evaluating the osseous structures of the middle ear and is often preferred for peripheral vestibular disease. Magnetic resonance imaging (MRI) is the gold standard for evaluating the brain and inner ear, providing detailed soft tissue contrast. MRI findings in otitis media/interna include thickening and contrast enhancement of the tympanic bulla lining and inner ear. In central vestibular disease, MRI may reveal lesions in the brainstem or cerebellum, such as infarcts (hyperintense on T2/FLAIR, diffusion restriction), neoplasia (contrast-enhancing mass), or inflammation (parenchymal contrast enhancement). CT is also useful for detecting hemorrhage or mineralization.

Cytological evaluation of middle ear fluid or material obtained via myringotomy may reveal inflammatory cells (neutrophils, macrophages) and bacteria or fungi. Histopathology of biopsy samples from the middle ear or brain may be necessary for definitive diagnosis of neoplasia or inflammatory disease. In cases of otitis media, histopathology may show chronic inflammation with fibrosis and epithelial hyperplasia. In brain tumors, histopathology reveals the specific tumor type (e.g., meningioma, glioma). CSF analysis is a form of cytology; findings include increased protein and nucleated cells, and may identify neoplastic cells in some cases.

Treatment depends on the underlying cause. For peripheral vestibular disease due to otitis media/interna, treatment includes systemic antibiotics (e.g., amoxicillin-clavulanate 20 mg/kg PO q12h, or enrofloxacin 5-10 mg/kg PO q24h) for 4-6 weeks, and possibly surgical intervention (bullae osteotomy) if medical therapy fails. For idiopathic vestibular syndrome, treatment is primarily supportive: antiemetics (e.g., maropitant 1 mg/kg SC q24h), antihistamines (e.g., meclizine 12.5-25 mg/dog PO q24h) to reduce nausea, and sedation if severe anxiety (e.g., diazepam 0.1-0.2 mg/kg IV). For central vestibular disease, treatment is directed at the underlying cause: for inflammatory disease, immunosuppressive doses of corticosteroids (e.g., prednisone 0.5-1 mg/kg PO q12h) or other immunosuppressants (e.g., cytarabine) may be used; for infectious causes, specific antimicrobials (e.g., clindamycin 10-20 mg/kg PO q12h for toxoplasmosis, fluconazole 5-10 mg/kg PO q24h for cryptococcosis); for stroke, supportive care and management of underlying risk factors (e.g., hypertension). Thiamine deficiency is treated with thiamine 50-100 mg IM/IV q12h. Metronidazole toxicity is treated by discontinuing the drug and providing supportive care; diazepam may be used to facilitate recovery.

The prognosis for peripheral vestibular disease is generally good, especially for idiopathic vestibular syndrome, where most animals improve within 2-3 weeks, though a residual head tilt may persist. Otitis media/interna has a good prognosis with appropriate treatment, but recurrence is possible. Central vestibular disease has a more guarded prognosis, depending on the cause. For ischemic stroke, many animals improve over weeks to months, but there is a risk of recurrence. Inflammatory brain disease may be managed but often requires long-term immunosuppression. Neoplasia carries a poor to guarded prognosis, depending on tumor type and treatment options. Overall, the prognosis is better for peripheral than central vestibular disease.

Follow-up should be scheduled at 1-2 weeks after initial diagnosis to assess response to treatment. For otitis media/interna, repeat otoscopic examination and imaging (CT or MRI) may be needed after 4-6 weeks to ensure resolution. For central vestibular disease, repeat neurological examinations are essential; if on immunosuppressive therapy, monitor for side effects and adjust doses. Serial CSF analysis may be performed to monitor response to therapy in inflammatory disease. Blood pressure should be monitored in cases of stroke. Long-term follow-up may be needed for chronic conditions such as neoplasia.

Pearls: 1) Differentiating peripheral from central vestibular disease is crucial; the presence of proprioceptive deficits or altered mentation indicates central involvement. 2) In geriatric dogs with acute onset of peripheral vestibular signs and no other deficits, idiopathic vestibular syndrome is likely; avoid unnecessary diagnostics. 3) Always perform a thorough otoscopic examination in cases of peripheral vestibular disease. 4) MRI is the imaging modality of choice for central vestibular disease. Pitfalls: 1) Mistaking central vestibular disease for peripheral can delay diagnosis of serious brain pathology. 2) Using ototoxic drugs (e.g., aminoglycosides) in patients with vestibular disease can worsen the condition. 3) Failing to consider metronidazole toxicity in dogs with vestibular signs and a history of metronidazole use. 4) Not checking blood pressure in cases of suspected stroke.

Antiemetics: Maropitant (Cerenia) 1 mg/kg SC q24h or 2 mg/kg PO q24h for up to 5 days. Antihistamines: Meclizine 12.5-25 mg/dog PO q24h; diphenhydramine 2-4 mg/kg PO q8h. Sedatives: Diazepam 0.1-0.2 mg/kg IV (for acute anxiety). Antibiotics for otitis media: Amoxicillin-clavulanate 20 mg/kg PO q12h for 4-6 weeks; enrofloxacin 5-10 mg/kg PO q24h (avoid in young animals due to cartilage damage). Corticosteroids: Prednisone 0.5-1 mg/kg PO q12h for inflammatory brain disease, tapering over weeks. Immunosuppressants: Cytarabine 50 mg/m² SC q12h for 2 days, repeated every 3 weeks. Antifungals: Fluconazole 5-10 mg/kg PO q24h; itraconazole 5-10 mg/kg PO q24h. Antiprotozoals: Clindamycin 10-20 mg/kg PO q12h for toxoplasmosis/neosporosis. Thiamine: 50-100 mg IM/IV q12h. For metronidazole toxicity: Discontinue metronidazole; diazepam 0.5 mg/kg IV or PO q8h may aid recovery. All dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered.

Key studies and consensus guidelines: 1) ACVIM consensus statement on the diagnosis and treatment of canine and feline vestibular disease (2020) emphasizes the importance of MRI for central vestibular disease. 2) A retrospective study by Rossmeisl et al. (2007) found that idiopathic vestibular syndrome in dogs has a good prognosis with supportive care. 3) A study by Sturges et al. (2006) reported that MRI is superior to CT for diagnosing otitis media/interna. 4) Research by Lowrie et al. (2013) highlighted the role of metronidazole toxicity in vestibular signs and the efficacy of diazepam. 5) The International Veterinary Epilepsy Task Force (IVETF) has published guidelines on the management of inflammatory brain disease, recommending immunosuppressive therapy. 6) A meta-analysis by Bateman et al. (2017) found that thiamine deficiency is an important cause of vestibular signs in cats, and prompt treatment improves outcomes.